AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05852301 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention, observational study only
Study NCT05698264 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: concomitant TTFields treatment device to standard of care EGFR positive NSCLC treatment
Description: Concomitant to drug therapy, patients will receive treatment with Tumor Treating Fields (TTFields), generated by the medical device NovoTTF-200T with a recommended duration of minimum 18 h a day. TTFields administered using insulated transducer arrays applied to the skin surrounding the region of a malignant tumor.
Study NCT05698264 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: concomitant TTFields treatment device to standard of care anti PD-1 NSCLC treatment
Description: Concomitant to drug therapy, patients will receive treatment with Tumor Treating Fields (TTFields), generated by the medical device NovoTTF-200T with a recommended duration of minimum 18 h a day. TTFields administered using insulated transducer arrays applied to the skin surrounding the region of a malignant tumor.
Study NCT05245422 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant Formula - Partially hydrolyzed protein
Description: Partially hydrolyzed cow's milk protein
Study NCT05245422 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Infant Formula - Intact protein
Description: Intact cow's milk protein
Study NCT05678062 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Point-of-care ultrasound
Description: An ultrasound examination (approximately 35-40 minutes in duration) will be performed. The ultrasound examination will consist of evaluation of lung- and cardiac ultrasound, as well as optic nerve sheath diameter.
Study NCT04827043 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Ultrasound guided quadratus lumborum block
Description: prospective randomized comparative study between Group (1) : quadratus lumborum block
Study NCT04827043 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Ultrasound guided thoracic paravertebral block
Description: PVB group: will receive 0.25ml/Kg/side of 0.375% bupivacaine with epinephrine 5ug/ml, yielding the same dose of bupivacaine of 1.875mg/ml at the level of T10 as a single injection sonar guided.
Study NCT06184425 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dural Puncture Epidural technique using pencil-point 25G Whitacre needle
Description: - DPE technique was performed in the sitting position at the L3/4 or L4/5 interspace via the midline approach using a 17-gauge Touhy needle and a loss of resistance to saline technique, then the dura was punctured with a 25-gauge pencil point Whitacre spinal needles using a needle-through-needle technique, and spontaneous flow of cerebrospinal fluid was confirmed, then the spinal needle was removed and a flexible 19-gauge, spring closed-tip catheter was inserted 5 cm into the epidural space toward the cranial side.
Study NCT06184425 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dural Puncture Epidural technique using pencil-point 27G Whitacre needle
Description: - DPE technique was performed in the sitting position at the L3/4 or L4/5 interspace via the midline approach using a 17-gauge Touhy needle and a loss of resistance to saline technique, then the dura was punctured with a 27-gauage pencil point Whitacre spinal needles using a needle-through-needle technique, and spontaneous flow of cerebrospinal fluid was confirmed, then the spinal needle was removed and a flexible 19-gauge, spring closed-tip catheter was inserted 5 cm into the epidural space toward the cranial side.
Study NCT06440031 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CaMaPi
Description: CaMaPi is a manually assisted brief psychological intervention that is based on the principles of Cognitive Behaviour Therapy (CBT). The intervention includes psycho-education and a comprehensive cognitive behavioural assessment of the suicidal ideation and self-harm attempt using virtual stories of four young people to be delivered in 8-10 sessions for over three months
Study NCT06440031 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: Treatment as Usual (TAU) is routine care, such as diagnosis, assessment, psychotherapy, monitoring and any form of intervention (e.g., medication prescription) available at the collaborating service.
Study NCT05360212 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anatomy-based fitting (ABF)
Description: MAESTRO 9 can display the tonotopic frequency of each individual electrode channel imported from OTOPLAN to further support fitting based on these measures. The audiologist can set a frequency-band distribution that is more closely aligned to the tonotopic frequency distribution as imported from OTOPLAN.
Study NCT05360212 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard Fitting
Description: These group is fitted using the standard frequency-band distribution as implemented in MAESTRO 9.
Study NCT05360212 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard fitting+ ABF
Description: Patients of this group are both fitting using the standard frequency-band distribution and the anatomy-based frequency distribution in MAESTRO 9. So, subjects will have both study maps on their audio processor throughout the whole study. They will have to change weekly between both fittings: standard fitting and anatomy-based fitting. Here, the performance with anatomy-based fitting is assessed by comparing performance with standard fitting and anatomy-based fitting.
Study NCT04553796 — intervention group
Intervention type: DEVICE
Intervention: fibroscan
Description: Fibroscan is a non-invasive test that helps assess the health of your liver. Specifically, it uses ultrasound technology to determine the degree of fibrosis or scarring that may be present in your liver from various liver diseases or conditions
Study NCT06046937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monolaurin
Description: applied thinly twice a day
Study NCT06632886 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: AI-Assisted Non-Contrast CT for Multi-Cancer Screening
Description: Participants identified by the AI model as having potential cancerous lesions, including those suspected of lung, liver, gastric, colorectal, esophageal, pancreatic, and breast cancer, will be required to undergo blood tests (for tumor markers) and additional imaging studies (such as contrast-enhanced CT, MRI, Endoscopy, etc.) to confirm the diagnosis of cancerous lesions.
Study NCT05211648 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aktiia Bracelet
Description: Aktiia Bracelet is a CE-marked medical device that will be used in accordance with its instructions for use. The optical signals at the wrist are recorded non-invasively by means by the Aktiia bracelet. The Blood Pressure measurements are further determined from these optical signals and are compared to weekly and monthly Blood Pressure averages measured manually by traditional Home Blood Pressure Monitoring.
Study NCT05669235 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Questionnaires
Description: A series of questionnaires will be carried out that assess both respiratory problems, depression and strength.
Study NCT05661370 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dermloop Learn
Description: Educational Mobile Application with a library of digital patient-cases and written learning modules the user can access on 36 common skin lesions, both benign and malignant.
Study NCT04740216 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise therapy plus jaw device
Description: The mouth-opening rehabilitation exercise lasts for twelve weeks, five days a week, three times a day. Subjects can arrange to perform before or after meals according to personal eating time and preferences. The experimental group performs 30 minutes each time, including 20 minutes of stretching exercises. Ten-minute mouth expander assisted passive exercise.
Study NCT04740216 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: exercise therapy
Description: the control group performed 20-minute stretching exercises each time.
Study NCT04145258 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Aspirin
Description: Two tablets of aspirin 100 mg per day from inclusion (D-0) to end of Week-8 (W-8)
Study NCT04145258 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo of aspirin
Description: Two placebo tablets with the same appearance of aspirin 100 mg per day from inclusion (D-0) to end of Week-8 (W-8)
Study NCT04145258 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: WHO TBM treatment
Description: 2 months of (R-H-Z-E) + 7 months of (R-H)
Study NCT06046937 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mupirocin ointment
Description: applied thinly twice a day
Study NCT05268172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IFN-γ and CIK cells, Tcm cells or CAR T cells
Description: A 50ng/ mL IFN-γ solution was prepared, and the required volume of IFN-γ solution was calculated according to the final concentration of 5ng/ mL according to the volume of pleural fluid or ascites of the patient. CIK cells were injected 1.0-2.0×109 on the second day and review three days later.T cells and CAR T cells were selected sequentially according to the re-examination of pleural fluid or ascites.
Study NCT05267951 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Open-loop Stimulation
Description: Spinal cord stimulation will be applied continuously over the skin throughout the intervention session.
Study NCT05267951 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Close-loop Stimulation
Description: Spinal cord stimulation will start and stop based on the signals that come from the sensors placed on upper limb muscle surfaces.
Study NCT05267951 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Task Practice
Description: Exercise therapy consists of repeated functional hand and arm movements
Study NCT05295108 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caring Connections
Description: peer-based letter writing social connectedness intervention to improve social health outcomes
Study NCT05295108 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Attention control
Description: informational materials provided to educate on life domains that are important to social health
Study NCT04145258 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Intensified TBM treatment
Description: 2 months of (HDR-L-H-Z-E) + 7 months of (R-H), with HDR=high-dose rifampicin and L=linezolid
Study NCT05629130 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: embolization with spherical microparticles embosphere
Description: embolization of affected joints with spherical microparticles embosphere
Study NCT06080685 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Character Strengths Intervention
Description: Session 1. Getting Started: Introducing and Exploring Character Strengths Session 2. Boost a Lower Strength Session 3. Cultivate your inner self + Loving-Kindness Meditation Session 4. Gratitude Letter + Three Good things Session 5. Conclusion Each session will consist of 1-hour, which will be delivered once a week for 5 weeks. Moreover, participants will be given homework which they will practice the rest of the week.
Study NCT06080685 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Character Strengths Intervention
Description: Session 1. Getting Started: Introducing and Exploring Character Strengths Session 2. Boost a Lower Strength Session 3. Cultivate your inner self + Loving-Kindness Meditation Session 4. Gratitude Letter + Three Good things Session 5. Conclusion Each session will consist of 1-hour, which will be delivered once a week for 5 weeks. Moreover, participants will be given homework which they will practice the rest of the week.
Study NCT05824169 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GC101
Description: Self-complementary AAV9 carrying a codon-optimized SMN coding sequence(coSMN1) driven by CMV enhancer and chicken β-actin promoter
Study NCT05639192 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Asunercept
Description: Asunercept (APG101) will be administered once per week as an i.v. infusion
Study NCT05639192 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered once per week as an i.v. infusion
Study NCT02035917 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Locking plate
Study NCT02035917 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-Locking plate
Study NCT05938998 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga; Support Group
Description: BEHAVIORAL: Group Exercise Sessions- Yoga. BEHAVIORAL: Social Support Sessions
Study NCT06432530 — intervention group
Intervention type: OTHER
Intervention: C-Reactive Protein (CRP), Erythrocyte Sedimentation Rate (ESR), Complete Blood Count (CBC) values, and indexes derived from the CBC.
Description: Patients' hematological parameters were recorded, and hematological inflammatory indexes (NLR: neutrophil/lymphocyte; MLR: monocyte/lymphocyte; PLR: platelet/lymphocyte; NLPR: neutrophil/(lymphocyte\*platelet); SII (neutrophil\*platelet/lymphocyte): systemic inflammatory index; SIRI (neutrophil\*monocyte/lymphocyte): systemic inflammatory response index; AISI (neutrophil\*platelet\*monocyte/lymphocyte): aggregate index of systemic inflammation. ) were derived from baseline CBC tests.
Study NCT04541875 — intervention group
Intervention type: OTHER
Intervention: MAR-Scale
Description: The MAR-Scale is a 20-item questionnaire based on commonly reported reasons for non-adherence to medications.
Study NCT06028295 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wheat Polar Lipid Complex Oil
Description: The study foresees the intake of 2 capsules per day during 84 days
Study NCT06028295 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wheat Polar Lipid Complex Powder
Description: The study foresees the intake of 2 capsules per day during 84 days
Study NCT06028295 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The study foresees the intake of 2 capsules per day during 84 days
Study NCT05528978 — intervention group
Intervention type: BEHAVIORAL
Intervention: Shambhavi Kriya
Description: The intervention investigators propose for the study includes an Online Course with 7 modules, or a 10 hours long course, and a 1-2 day In-Person Course, in which participants will learn a simple 21 minute practice called Shambhavi Mahamudra Kriya, also known as Shambhavi Kriya.~Shambhavi Kriya is a powerful and purifying energy technique incorporating the breath. This practice is said to align the participants system such that their body, mind and emotions function in harmony.
Study NCT05238610 — intervention group
Intervention type: PROCEDURE
Intervention: PFO closure
Description: PFO-closure will be performed after 3-6 month of observation and monitoring for paroxysmal atrial fibrillation
Study NCT05175235 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CURATE.AI
Description: Efficacy and toxicity measurements at the end of each two-/three- week dosing cycle, together with an information on given drugs and their doses, and other patient data, will be used by CURATE.AI to recommend the dose of nivolumab/pembrolizumab for the next cycle. The clinical investigators will decide whether or not to administer or prescribe the dose recommendation from CURATE.AI.
Study NCT05175235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab, Pembrolizumab
Description: Treatment with the selected regimen will take up to a maximum duration of 12 months, in two-/three- week cycles. CURATE.AI dose recommendations will be generated before each chemotherapy cycle; fixed throughout the cycle; Maximum total cumulative dose per cycle of nNivolumab/pembrolizumab in the predetermined safety range is set at 100% of standard starting dose (i.e. , 240 mg/m2 once every 2 weeks for single agent Nivolumab and 200 mg/m2 once every 3 weeks for single agent Pembrolizumab). Minimum total cumulative dose per cycle of nivolumab/pembrolizumab in the predetermined safety range is set at 30% of the standard starting dose (i.e. 8072 mg/m2 once every 2 weeks for single agent Nivolumab and 60 mg/m2 once every 3 weeks for single agent Pembrolizumab). Subject-specific dosing range may alter those numbers to suit the specific circumstances of the subject, thus giving the subject specific safe dosing range.
Study NCT04905160 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COMPASSION Digital Biomarker
Description: Vitals data collected by the Vitalbeat workbench for biomarker based algorithm variables will be used to drive intervention based on PAP systolic and diastolic pressures.
Study NCT05941494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Patient will receive propofol as their maintenance agent during surgery. The typical dose is 150-200 mg/kg/min.
Study NCT05941494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Patient's anesthesia will be maintained with 1 MAC of sevoflurane during surgery.
Study NCT05941494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ephedrine
Description: The patient will receive ephedrine infusion as the primary vasopressor of choice. The typical dose of ephedrine infusion is 10-50 mg/hr (dilution 2 mg/ml).
Study NCT05941494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: Patient will receive phenylephrine infusion as the primary vasopressor of choice. The typical dose of phenylephrine infusion is 10-40 mcg/min (dilution 100 mcg/ml).
Study NCT05649020 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dose of prilocaine
Description: With the patient in the sitting position, spinal anesthesia was performed using the midline approach at the L3-L4; L4-L5 interspace with a spinal needle. The dose of HP that a patient received was determined by the previous patient's response. If successful anesthesia was obtained, the next patient's dose was decreased. The first patient will receive a dose of 20 mg. The dose decrement/increment for each subsequent patient will be set at 2 mg. A nurse blinded to the dose, will assess the sensitive level achieved with each block. Furthermore, all patients will be unaware of the injected dose of HP. For purposes of the study, anesthesia was considered successful when there was complete loss of pinprick and cold sensation at the L1 dermatome. Values of ED 50 will be determined by calculating the midpoint concentration after at least 8 crossover points sufficient/insufficient anesthesia will be obtained. A single measurement will be obtained from each patient.
Study NCT04957706 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: anterior drawer test at 90° of hip flexion
Description: anterior drawer test at 90° of hip flexion
Study NCT04957706 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Lachman test
Description: Lachman test
Study NCT04957706 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: anterior drawer test
Description: anterior drawer test
Study NCT04957706 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: pivot-shift test
Description: pivot-shift test
Study NCT05449431 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TLC1_TM6
Description: Following this inclusion, patients are performing 1-minute chair lift test (TLC1) before 6-minute Walk Test (TM6). Each exercise will be separated by 30 minutes during which the patient will be sitting in a waiting room.
Study NCT05449431 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TM6_TLC1
Description: Following this inclusion, patients are performing 6-minute Walk Test (TM6) before 1-minute chair lift test (TLC1). Each exercise will be separated by 30 minutes during which the patient will be sitting in a waiting room.
Study NCT06050811 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 2'-Fucosyllactose
Description: 2'-Fucosyllactose given orally with water or food for four weeks, followed by a three week washout period.
Study NCT06050811 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin given orally with water or food for four weeks, followed by a three week washout period.
Study NCT06049511 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: oral self care protocol
Description: An oral self-care protocol, grounded in Orem's Self-Care Deficit theory and incorporating self-care behaviors, was implemented for the patients in the treatment group. The protocol consisted of several components, including the assessment of oral mucositis by the researcher and self-assessment of the oral cavity by the patients. It also involved teaching proper tooth brushing techniques, providing written materials, supplying an oral care kit, and offering patient and family education. Interventions were made for 21 days from the beginning of chemotherapy treatment.
Study NCT06049511 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: standard care
Description: the patients received standard nursing care provided at the clinic to prevent oral mucositis.
Study NCT05647174 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MGPOCUS-assisted bronchoscope-guided intubation
Description: Application of ultrasound instruments that can detect magnetic signals to determine the position of the magnetised bronchoscopy to guide the direction of its advancement and thus optimise difficult endotracheal intubation.
Study NCT05647174 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoscope-guided intubation
Description: Routine bronchoscope- guided intubation.
Study NCT05081050 — intervention group
Intervention type: OTHER
Intervention: Only Follow-up
Description: No intervention is planned.
Study NCT04849169 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Prolonged balloon inflation for hemorrhage management due to coronary artery perforation.